-
Shenzhen Abrobo Medical Robot Secures RMB 100 Million in Series A Financing for Robotic Development
•
Shenzhen Abrobo Medical Robot Co, Ltd has reportedly raised RMB 100 million via a Series A financing round, marking a significant step forward for the company. The round was led by Guozhong Capital, with additional investments from Lenovo Capital and Long Hill Capital. The funds will be directed towards accelerating…
-
Ucello Therapeutics Secures RMB 150 Million in Series A+ Financing for CAR-T Cell Therapy
•
Ucello Therapeutics, a developer of allogeneic universal chimeric antigen receptor (CAR)-T cell therapies based in Chengdu, has reportedly raised RMB 150 million (USD 21.2 million) in a Series A+ financing round. The funding was led by Juke Investment, with contributions from Guozhong Capital and Penglai Capital, as well as existing…
-
Betta Pharmaceuticals Secures Exclusive Rights to C4 Therapeutics’ CFT8919 in Greater China
•
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced an exclusive licensing agreement with US firm C4 Therapeutics Inc., (NASDAQ: CCCC) focusing on the development and commercialization of C4’s preclinical stage CFT8919 in Greater China, including Hong Kong SAR, Macau SAR, and Taiwan. CFT8919 is an orally bioavailable BiDAC degrader…
-
Lynk Pharmaceuticals Secures RMB 200 Million in Series C1 Financing Round
•
China-based Lynk Pharmaceuticals Co., Ltd has successfully raised RMB 200 million (USD 28.3 million) through a Series C1 financing round. The investment was led by China Grand Prosperity Investment, with participation from Tailong VC and LIANDO. The proceeds from this funding round will be utilized to accelerate the clinical development…
-
Sanofi’s Commitment to China: Expansion, Digital Innovation, and Local R&D
•
Wayne Shi, president of France-based Sanofi’s (NASDAQ: SNY) Greater China business, has been discussing the firm’s ongoing commitment to the China market with local media. Speaking to China Daily, Shi emphasized that Sanofi has “always been optimistic about the Chinese market and will continuously expand our investment in China.” Sanofi…
-
Boyi Biotech Secures Over RMB100 Million in Series A Financing Led by JOLMO
•
Boyi Biotech, a prominent biological microspheres developer headquartered in Changzhou, has reportedly secured more than RMB100 million in a Series A financing round. The round was led by JOLMO, with additional investments from Bondshine Capital, Wei Chi Equity Fund, and Hua Guoping, the founder of Jiangsu Hualan New Pharmaceutical Material…
-
Zelixir Biotech Secures Over RMB 100 Million in Series A Financing for Synthetic Biology Pipeline
•
Shanghai-based Zelixir Biotech, a leading provider of protein structure prediction and design services, has reportedly secured more than RMB 100 million (USD 14.1 million) in a Series A financing round. The funding was led by Qingdao Qingchi Venture Capital Fund, with additional investments from HM Capital, Hongfeng Investment, and Q…
-
PathoAI Secures Tens of Millions in Angel Financing for AI-Powered Pathology Solutions
•
PathoAI, a company at the forefront of intelligent pathology and examination through artificial intelligence (AI), has reportedly raised tens of millions of renminbi in an angel financing round. The funding was led by Hangzhou Taikun Equity Investment Fund Partnership, with participation from Deshi Capital. PathoAI’s Focus on AI Products and…
-
GenScript Biotech’s Legend Biotech Secures Private Placement with Hillhouse Investment
•
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has revealed that its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), is set to conduct a private placement of 692,800 shares at USD 32 per share to LGN Holdings Ltd, a company solely managed by Hillhouse Investment Management, Ltd. This transaction…
-
MicroPort Scientific Plans IPO for Subsidiary MicroPort CRM on Hong Kong Stock Exchange
•
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced its intention to spin off its France-based subsidiary, MicroPort Cardiac Rhythm Management Limited (MicroPort CRM), to pursue an initial public offering (IPO) on the Hong Kong Stock Exchange. This move has been confirmed by the bourse, and MicroPort expects…
-
Coherent Biopharma Secures $100 Million in Series B and B+ Financings for Clinical Pipeline
•
Coherent Biopharma Ltd, a specialist in bispecific-ligand drug conjugates (Bi-XDC) headquartered in Suzhou, has declared the successful completion of Series B and Series B+ financing rounds, totaling $100 million. The initial Series B round was led by HM with support from Yuanfeng Capital, V Capital, 6 Dimensions Capital, Agricultural Bank…
-
ExoRNA Bio Secures Tens of Millions in Financing to Advance Huntington’s Disease Pipeline
•
ExoRNA Bio, a Shenzhen-based central nervous system (CNS) drug developer, has reportedly raised tens of millions of renminbi in an angel+ financing round. The round was led by Yuexiu Industrial Fund, with participation from Jingxin Pharma, Dingxin Capital, Nanjing University Biopharmaceutical Industry Alumni Association, and existing investor CDH Investments. The…
-
First Condor Biotechnology Secures Tens of Millions in Pre-Series A Financing for CAR-T Cell Trials
•
First Condor Biotechnology, a Guangdong-based cell therapy developer, has reportedly secured tens of millions of renminbi in a Pre-Series A financing round. This funding round was led by Guangdong Lianjing Investment Group, marking a significant step forward for the company. The proceeds from this investment will be directed towards the…
-
Shenzhen’s Angio8 Secures Tens of Millions in Series A Financing for Surgical Robot Development
•
Angio8, a Shenzhen-based developer of vascular interventional surgical robots, has reportedly raised tens of millions of renminbi through a Series A financing round. The investment was led by Oriental Fortune Capital, with participation from Kangyu Capital, marking a significant milestone in the company’s growth and development trajectory. Commitment to First-In-Class…
-
Lingyi Biotechnology Secures RMB 100 Million in Series A Funding for Gene Therapy Pipeline
•
China-based gene therapy developer Lingyi Biotechnology Co., Ltd has reportedly raised close to RMB 100 million (USD 14.5 million) in a Series A finance round. This significant investment was co-led by Efung Capital and Huafang Asset Management, with additional participation from Transfar Science City, Sequoia China, and Huaiji Capital. The…
-
VivaVision Biotech Secures Over RMB 100 Million in Series D2 Financing for Ophthalmology Pipeline Expansion
•
China’s VivaVision Biotech Inc. has announced the successful completion of its Series D2 financing round, securing an investment exceeding RMB 100 million. The funding round was led by V-Capital, Shengze Investment, Sunbow Capital, and VVB Fund. The capital raised will be strategically allocated to accelerate the company’s multiple clinical studies…
-
NeuExcell Therapeutics Secures Over $14.5 Million in Pre-Series A+ Funding for Neurological Treatments
•
NeuExcell Therapeutics, a Sino-US biotech company specializing in treatments for neurological damage and degenerative diseases, has successfully raised over RMB 100 million (USD 14.5 million) in a pre-Series A+ financing round. The funding round saw participation from notable investors such as ZJ Leading VC, Jemincare, HX Pharma, Leader Venture Capital,…
-
Q1 2023 financial report: AstraZeneca leads innovation in China, Sanofi’s sales in China decline
•
Several multinational companies (MNCs) have released their Q1 2023 financials, showing a varied performance over the quarter. AstraZeneca’s China Innovation BoomAstraZeneca (AZ, NASDAQ: AZN) CEO Pascal Soriot warned that Europe is lagging behind China in fostering innovation and access to medicines. This statement came during the company’s Q1 2023 earnings…
-
Reforgene Medicine Secures Pre-Series B Funding to Advance Thalassemia Gene Therapy
•
Reforgene Medicine, a Guangzhou-based gene editing therapy company, has reportedly secured hundreds of millions of renminbi in a Pre-Series B financing round. The round was led by Yuexiu Industrial Fund, with participation from other notable investors including Yuanying Venture Capital, Shanfeng Venture Capital, Emerging Fund, Ganyue Investment, Guoju Venture Capital,…
